ERYTECH PHARMA's ticker is ERYP and the CUSIP is 29604W108. A total of 10 filers reported holding ERYTECH PHARMA in Q1 2023. The put-call ratio across all filers is 0.25 and the average weighting 0.0%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2023 | $7,731 | -25.5% | 10,590 | 0.0% | 0.00% | – |
Q1 2023 | $10,378 | +196.9% | 10,590 | 0.0% | 0.00% | – |
Q4 2022 | $3,496 | -41.7% | 10,590 | 0.0% | 0.00% | – |
Q3 2022 | $6,000 | -50.0% | 10,590 | 0.0% | 0.00% | – |
Q2 2022 | $12,000 | -36.8% | 10,590 | +1.7% | 0.00% | – |
Q1 2022 | $19,000 | -24.0% | 10,415 | -1.9% | 0.00% | – |
Q4 2021 | $25,000 | +108.3% | 10,615 | +430.8% | 0.00% | – |
Q3 2021 | $12,000 | – | 2,000 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
BVF INC/IL | 1,314,656 | $3,103,000 | 0.11% |
ARMISTICE CAPITAL, LLC | 2,737,572 | $6,433,000 | 0.10% |
Tower Research Capital LLC (TRC) | 321 | $1,000 | 0.00% |
GROUP ONE TRADING, L.P. | 10,615 | $25,000 | 0.00% |
JANE STREET GROUP, LLC | 45,639 | $110,000 | 0.00% |
CONCOURSE FINANCIAL GROUP SECURITIES, INC. | 0 | $0 | 0.00% |
UBS Group AG | 3,583 | $8,000 | 0.00% |
CREDIT SUISSE AG/ | 16,900 | $40,000 | 0.00% |
Citadel Advisors | 299,800 | $708,000 | 0.00% |
Citadel Advisors | 73,325 | $173,000 | 0.00% |